– Aberrant TRIM7 expression identified as a key driver of immune checkpoint blockade (ICB) acquired resistance; inhibition of TRIM7 with small molecule inhibitors may prevent or reverse acquired resistance to PD-1/L1 blockade –
Shattuck Labs anuncia la presentación oral de datos preclínicos en la Reunión Anual 2024 de la American Association for Cancer Research (AACR)
